CTRP13 Preserves Endothelial Function by Targeting GTP Cyclohydrolase 1 in Diabetes

Area of Science:

• Cardiovascular Biology
• Metabolic Diseases
• Endocrinology

Background:

• Endothelial dysfunction is a key factor in diabetic vasculopathy.
• C1q/tumor necrosis factor-related protein 13 (CTRP13) is an adipokine with known protective effects against atherosclerosis and vascular calcification.
• The role of CTRP13 in diabetes-related endothelial dysfunction remains uninvestigated.

Purpose of the Study:

• To investigate the effect of CTRP13 on endothelial function in diabetic models.
• To elucidate the underlying mechanisms by which CTRP13 influences endothelial health in diabetes.

Main Methods:

• Treatment with CTRP13 in diabetic mouse models (db/db and streptozotocin-injected).
• Ex vivo assessment of endothelium-dependent relaxation in aortae and mesenteric arteries.
• Measurement of reactive oxygen species (ROS) and nitric oxide (NO) production.
• Analysis of endothelial NO synthase (eNOS) coupling, GTP cyclohydrolase 1 (GCH1) expression, tetrahydrobiopterin (BH4) levels, and protein kinase A (PKA) activity.
• Investigation of PKA-mediated signaling pathways involving peroxisome proliferator-activated receptor α (PPARα).

Main Results:

• CTRP13 treatment significantly improved endothelium-dependent relaxation in diabetic mouse arteries.
• CTRP13 administration reduced ROS overproduction and enhanced NO bioavailability by improving eNOS coupling.
• Mechanistically, CTRP13 increased GCH1 expression and BH4 levels, crucial for eNOS coupling.
• CTRP13 rescued high glucose-induced inhibition of PKA activity, which in turn promoted GCH1 transcription via PPARα phosphorylation.

Conclusions:

• CTRP13 effectively preserves endothelial function in diabetic conditions.
• The protective effects of CTRP13 are mediated through the GCH1/BH4 axis-dependent eNOS coupling pathway.
• CTRP13 demonstrates significant therapeutic potential for treating diabetic vasculopathy.